Literature DB >> 35070250

The need for a strategic therapeutic approach: multiple sclerosis in check.

Hernan Inojosa1, Undine Proschmann1, Katja Akgün1, Tjalf Ziemssen2.   

Abstract

Multiple sclerosis (MS) is the most common chronic autoimmune neurological disease. Its therapeutic management has drastically evolved in the recent years with the development of specific disease-modifying therapies (DMTs). Together with the established injectables, oral and intravenous alternatives are now available for MS patients with significant benefits to modulate the disease course. Certain drugs present with a higher efficacy than the others, profiles and frequencies of adverse events differentiate as well. Thus due to the several and different treatment alternatives, the therapeutic approach adopted by neurologists requires a tactical focus for a targeted, timed, and meaningful treatment decision. An integration of rational and emotional control with proper communication skills is necessary for shared decision-making with patients. In this perspective paper, we reinforce the necessary concept of strategic MS treatment approach using all available therapies based on scientific evidence and current experience. We apply a didactic analogy to the strategic game chess. The opening with oriented attack (i.e. already in early disease stages as clinical isolated syndrome), a correct choice of chess pieces to move (i.e. among the several DMTs), a re-assessment reaction to different scenarios (e.g. sustained disease activity, adverse events, and family planning) and the advantage of real-world data are discussed to try the best approach to ultimately successfully approach the best personalized MS treatment.
© The Author(s), 2022.

Entities:  

Keywords:  DMTs; chess; disease-modifying therapies; multiple sclerosis; strategy; treatment

Year:  2022        PMID: 35070250      PMCID: PMC8777338          DOI: 10.1177/20406223211063032

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  73 in total

Review 1.  Optimizing therapy early in multiple sclerosis: An evidence-based view.

Authors:  Tjalf Ziemssen; Nicola De Stefano; Maria Pia Sormani; Bart Van Wijmeersch; Heinz Wiendl; Bernd C Kieseier
Journal:  Mult Scler Relat Disord       Date:  2015-07-17       Impact factor: 4.339

2.  Escalating immunotherapy of multiple sclerosis.

Authors:  Peter Rieckmann; Anthony Traboulsee; Virginia Devonshire; Joel Oger
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

Authors:  Robert J Fox; Amber R Salter; Tuula Tyry; Jennifer Sun; Xiaojun You; Genevieve Laforet; Denise Campagnolo
Journal:  Int J MS Care       Date:  2013

Review 4.  Immunosenescence in multiple sclerosis: the identification of new therapeutic targets.

Authors:  María Dema; Herena Eixarch; Luisa M Villar; Xavier Montalban; Carmen Espejo
Journal:  Autoimmun Rev       Date:  2021-07-05       Impact factor: 9.754

Review 5.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

6.  Natalizumab: A new treatment for relapsing remitting multiple sclerosis.

Authors:  Michael Hutchinson
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

7.  The importance of collecting structured clinical information on multiple sclerosis.

Authors:  Tjalf Ziemssen; Jan Hillert; Helmut Butzkueven
Journal:  BMC Med       Date:  2016-05-31       Impact factor: 8.775

8.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

9.  Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis.

Authors:  Mathias Mäurer; Klaus Tiel-Wilck; Eckard Oehm; Nils Richter; Michael Springer; Patrick Oschmann; Arndt Manzel; Stefanie Hieke-Schulz; Vera Zingler; Julia A Kandenwein; Tjalf Ziemssen; Ralf A Linker
Journal:  Ther Adv Neurol Disord       Date:  2019-12-19       Impact factor: 6.570

View more
  4 in total

1.  OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

Authors:  Tjalf Ziemssen; Stephan Richter; Mathias Mäurer; Mathias Buttmann; Boris Kreusel; Anne-Maria Poehler; Maren Lampl; Ralf A Linker
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

2.  Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.

Authors:  Aurora Zanghì; Emanuele D'Amico; Francesco Patti; Carlo Avolio
Journal:  Int J Environ Res Public Health       Date:  2022-05-17       Impact factor: 4.614

Review 3.  MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.

Authors:  Tjalf Ziemssen; Jo Vandercappellen; Valeria Jordan Mondragon; Gavin Giovannoni
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

4.  Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool.

Authors:  Jeremy Hobart; Helmut Butzkueven; Jodi Haartsen; Tjalf Ziemssen; Thirusha Lane; Gavin Giovannoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.